ABSTRACT
INTRODUCTION
Breast cancer is one of the most commonly encountered types of malignancy during pregnancy. 1, 2 Approximately 0.2% to 2.6% of all breast cancers occur during pregnancy (BCP). 3, 4 There was a general belief among physicians in the first half of the 20th century that breast cancer, under the stimulus of pregnancy, was especially aggressive, 5 and surgical treatment was pointless and thus contraindicated. 6 Indeed, the gestational physiologic alterations in the breast result in later diagnosis and higherstage tumors. A comprehensive review from 1953 showed improved survival rates for patients with breast cancer in association with pregnancy, from 0% 10-year survival before 1920 to 22.4% in the period from 1941 to 1950. 7 The survival rates were poorer than in the nonpregnant patients, probably because of the advanced stage of disease and delay in treatment; prompt commencement of treatment was necessary to improve survival rates. Since then, surgical treatment of BCP has become commonplace, and in the last decade, chemotherapeutic treatment during the second and third trimesters of pregnancy has also been introduced and deemed unharmful to the fetus.
Whether pregnancy itself negatively influences prognosis remains a subject of debate. We still have no comprehensive understanding of the interaction between pregnancy and breast cancer carcinogenesis. Some studies have shown a poorer prognosis for BCP, [11] [12] [13] [14] [15] [16] whereas others have found similar survival rates when compared with a control group of nonpregnant patients. [17] [18] [19] [20] [21] [22] [23] Up to now, reports on prognosis have had two major limitations, including small cohorts and the pooling of breast cancer diagnosed during and within 1 year after pregnancy (ie, pregnancy-associated breast cancer).
The aim of this study was to estimate the prognostic impact of pregnancy when breast cancer is diagnosed. We recently described the obstetric and neonatal outcomes of BCP. 24 Here, we used this series to compare survival between women with BCP and patients who did not have associated pregnancies.
PATIENTS AND METHODS

Design, Setting, and Participants
Two international multicenter cohort studies collaborated in this initiative. The German Breast Group (GBG) started a registration study for breast cancer during pregnancy in April 2003. In addition, although separately, the international Cancer in Pregnancy (CIP) study (www.cancerinpregnancy.org) started a registry in 2005 for all types of cancer diagnosed during pregnancy. All registered patients diagnosed with primary BCP between January 1, 2000, and September 30, 2011, were eligible for inclusion, independent of outcome of the pregnancy or treatment of breast cancer. Women with in situ or primary metastatic disease and those relapsing during pregnancy were excluded from all analyses. Women who became pregnant during treatment or received their diagnosis postpartum were also excluded to ensure homogeneity. We compared the patients of both registries to prevent double entries.
Both observational studies were approved by ethics committees, and written informed consent was obtained from patients before prospective inclusion. As regards the retrospective part, a majority of patients were registered without obtaining informed consent. Details on the construct and quality assurance can be found in the Appendix (online only). The studies were registered with ClinicalTrials.gov (CIP study, NCT00330447; GBG study, NCT00196833).
For the nonpregnant comparison group, we recruited all nonpregnant patients with stage I to III disease from the institutional database of the Multidisciplinary Breast Centre, University Hospitals Leuven, Leuven, Belgium, age Յ 45 years, between January 1, 2000, and August 1, 2010 (n ϭ 865).
Clinical Assessment
The patients' disease was staged using the American Joint Committee on Cancer staging system (seventh edition). Diagnosis was made by a combination of ultrasonography, mammography, and/or magnetic resonance imaging, followed by core needle biopsy. 9, 24 Type of treatment was decided by the patient's treating physician. To standardize treatment, treatment guidelines were made available by expert opinion reports. 25, 26 Both first and senior authors initiated multidisciplinary consensus meetings to construct international guidelines on the treatment of BCP. Whether chemotherapy was administered during pregnancy depended on the gestational age and stage of disease.
Chemotherapy dosages were equal to those for the nonpregnant patients and were based on body surface area. Additional therapies (also administered in the postpartum period), such as trastuzumab, endocrine treatment, and radiation therapy, were collected for all patients. Patient status as of December 31, 2011, was determined by reviewing medical records of patients as well as follow-up requested from the treating physicians, if they were treated elsewhere. We used a predefined case-registration follow-up form, including date of diagnosis, tumor pathologic features, oncologic treatment (including type of surgery and use of chemotherapy, radiotherapy, endocrine therapy, and trastuzumab), and patient outcome (including time and site of metastasis and survival status). For the pregnant patients, gestational age was calculated from the estimated due date, based on first-trimester ultrasound examination when performed, or from the last menstrual period.
Primary outcome was disease-free survival (DFS), defined as time in months from the date of first diagnosis to any invasive locoregional (ipsilateral breast, local/regional lymph nodes) recurrence of disease, any invasive contralateral breast cancer, any distant recurrence of disease, or any secondary malignancy, whichever occurred first. 27 Patients without events were censored at the date of last contact. Secondary outcome was overall survival (OS), defined as time in months from the date of first diagnosis to death resulting from any cause.
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Statistical Analysis
Missing values were imputed once using the method of chained equations to avoid bias and increase efficiency.
28,29 DFS and OS were compared between pregnant and nonpregnant patients using multivariable Cox proportional hazards regression to adjust for age at diagnosis, stage, grading, histologic tumor type, estrogen receptor (ER)/progesterone receptor (PR) status, human epidermal growth factor receptor 2 (HER2) status, trastuzumab, type of chemotherapy, radiotherapy, and hormone therapy.
Given that the average age at diagnosis was clearly different for pregnant and nonpregnant patients, simply adjusting for age by using age as a covariate may not have been sufficient. 30 Instead, we adjusted for age using inverse probability weighting to statistically correct for the strong imbalance in this variable. We estimated the probability of being pregnant according to age (P pregnant ) for the patients in the data set. The appropriate transformation of age was determined with the method of fractional polynomials. 31 The weights used in the Cox model were one for pregnant patients and the odds of P pregnant for nonpregnant patients to avoid large and unstable weights. 32, 33 This approach succeeded in overcoming the age imbalance, because we observed that the weighted distribution of age was nearly identical for pregnant and nonpregnant patients. A sensitivity analysis in which we adjusted for age using stratification instead of weighting yielded similar results.
Because pregnant patients were recruited in seven countries, we investigated the influence of country by checking the interaction of pregnancy with country (Belgium, Germany, other [including the Netherlands, United Kingdom, Czech Republic, Poland, and Italy]). Exploratory prespecified subgroup analyses were performed by adding interaction terms. Subgroups investigated were ER/PR status, molecular subtype, age, American Joint Committee on Cancer stage, and type of chemotherapy. Finally, one additional analysis compared pregnant patients with nulliparous nonpregnant patients only. All analyses were performed using the SAS statistical software package (version 9.2; SAS Institute, Cary, NC), making use of IVEware (version 0.2; http://www. isr.umich.edu/src/smp/ive/) for imputation of missing values.
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RESULTS
There were 447 women with BCP registered, of whom 311 were eligible for this analysis (we excluded three women age Ն 46 years, 36 with primary metastatic disease, 57 diagnosed before 2000, and 40 without follow-up); 240 (77.2%) of 311 patients were included prospectively. These 311 patients were compared with 865 women with breast cancer who were not pregnant (ratio 1:2.78). Demographic features are summarized in Table 1 . Distribution of pregnant patients among seven European countries was as follows: Germany, n ϭ 137 (44.05%); Belgium, n ϭ 77 (24.76%); the Netherlands, n ϭ 65 (20.90%); Great Britain, n ϭ 10 (3.22%); Poland, n ϭ 10 (3.22%); Czech Republic, n ϭ 10 (3.22%); and Italy, n ϭ 2 (0.64%). Median age was 33 years (interquartile range, 31 to 36) for the pregnant and 41 years (interquartile range, 38 to 44) for the nonpregnant patients. Median follow-up was 61 months (5 years, 1 month; range, 4 to 135 months).
Treatment
Type of treatment is depicted in Table 2 . Among the pregnant patients, taxanes were administered to 95 (47.03%) with adjuvant chemotherapy and to 69 (71.13%) with neoadjuvant chemotherapy. Among the nonpregnant patients, taxanes were administered to 168 (30.88%) with adjuvant chemotherapy and to 79 (77.45%) with neoadjuvant chemotherapy. Within the BCP group, 200 patients (64.31%) received chemotherapy during pregnancy, all in the second or third trimester.
Survival
During follow-up, 42 pregnant patients (14%) and 103 nonpregnant patients (12%) died. For the total group (pregnant and nonpregnant patients together), median follow-up for DFS was 61 months. Observed 5-year DFS was 78%, and median DFS time was 131 months. Observed 5-year OS was 87%; median OS time was not reached within the time frame of the study (Fig 1) . Table 3 summarizes the effect of pregnancy from the multivariable Cox proportional hazards regression of DFS and OS, adjusted for age at diagnosis, stage, grading, histologic tumor type, ER/PR status, HER2, trastuzumab, and chemotherapy. We did not find evidence of worse prognosis for women diagnosed with BCP regarding disease recurrence (hazard ratio [HR], 1.34; 95% CI, 0.93 to 1.91; P ϭ .14) or OS (HR, 1.19; 95% CI, 0.73 to 1.93; P ϭ .51). The average 5-year DFS probability based on the multivariable model was 65% for pregnant patients; it would have increased to 71% if these patients had not been pregnant. Likewise, the average 5-year OS probability was 78% for pregnant patients; it would have increased to 81% if these patients had not been pregnant. The sensitivity analysis using stratification rather than weighting for age to account for the strong age differences between pregnant and Fig 2) . However, the effects were smallest for pregnant patients from Belgium (HR, 1.10 for DFS and 0.98 for OS). The main Cox model resulted in an average predicted 5-year DFS probability of 65% for pregnant patients. According to the model, this would have increased to 71% if these patients had not been pregnant (but all other characteristics were identical). For OS, the average predicted 5-year survival probability would have increased from 78% to 81%. The subgroup analyses did not suggest clear effects (Fig 2) . When comparing pregnant patients with nulliparous nonpregnant patients (n ϭ 200; 23.1%), no differences were found for DFS (HR, 1.58; 95% CI, 0.93 to 2.77) or OS (HR, 1.58; 95% CI, 0.76 to 3.52). The lack of a prognostic effect of pregnancy was present both in the GBG and CIP groups.
DISCUSSION
We documented the prognosis of BCP in the largest series, to our knowledge, collected within the framework of a European collaboration. Tumor characteristics were comparable to other reported results of BCP. 35, 36 Poorly differentiated invasive ductal adenocarcinomas were prevalent and often hormone receptor negative. After adjusting for known prognostic factors, we found a modest, if any, effect of pregnancy on DFS and OS. Regarding the DFS analysis, the observed HR of 1.34 suggests better outcome for the nonpregnant group; however, the CI shows that any distinct effect of pregnancy cannot be concluded. Also, the observed HR for OS was only 1.19. This reassuring effect was especially true for the Belgian and German patients (Fig  2) . The largest difference was seen in the countries that contributed with lower numbers of patients with BCP. The effect of patient load on the outcome therefore deserves further investigation. The results of this study allow clinicians to inform patients with BCP on their prognosis, if receiving a standard therapy.
The prognosis of BCP has previously been addressed in several studies. We encountered 11 studies that did not distinguish between breast cancer diagnosed during pregnancy or during the postpartum/ lactation period, and these are not discussed further. We reviewed 17 studies published since 1985 that have made a subdifferentiation between breast cancer during and after pregnancy (n ϭ 6) 13, 15, 16, [21] [22] [23] or that concentrated solely on BCP, with control groups (n ϭ 7) 11, 12, 14, [17] [18] [19] [20] or without control groups (n ϭ 4). [35] [36] [37] [38] Probably because of small numbers, the available results are conflicting. Eight of the 17 studies found no difference in survival when compared with the age-matched nonpregnant patients with breast cancer [17] [18] [19] [20] [21] [22] [23] 36 ; six found worse survival for the patients with BCP [11] [12] [13] [14] [15] [16] ; three observational studies did not comment further on BCP prognosis (Table  4) . 35, 37, 38 Putative factors for worse prognosis included delayed diagnosis and delayed or modified cancer treatment to assure the birth of a healthy infant. Also, the pregnant state with immunosuppression, increased vascularization, and increased hormonal exposure have been postulated as contributing factors. During pregnancy, significantly increased concentrations of estrogen, progesterone, and insulin-like growth factor 1 are present. These hormones are highly linked to breast cancer development and progression. 39 However, on the basis of our results, these factors do not seem to contribute significantly to tumorigenesis or accelerated growth in vivo, as previously thought. Our findings are in agreement with those of Schedin 40 and Lyons et al, 41 who hypothesized that mammary gland involution, rather than pregnancy per se, was crucial for breast cancer growth. The postpartum or postlactation breast involution relies on tissueremodeling processes of wound healing and inflammation that also have a pro-oncogenic effect and promote tumor-cell dissemination. Thus, postpartum breast cancer rather than BCP carries a worse prognosis. How long this increased risk persists in the postpartum period has not been identified; the effect has been reported as continuing up to 10 years before a cross-over effect occurs, and the previous pregnancy becomes a protective factor. 16, 42 Also, for first-time mothers age Ͼ 35 years, the risk is permanently increased when compared with nulliparous women. The fact that the majority of our nonpregnant patients were parous (76.9%) might be regarded as a confounding factor, because we did not take time since last pregnancy into account. However, as suggested by Borges and Schedin, 43 we also compared pregnant patients with nulliparous nonpregnant patients (23.1%), and no differences in DFS or OS were found.
Gestational physiologic changes alter the pharmacokinetics of chemotherapy during pregnancy. In a pilot study, we calculated that for four cytotoxic drugs, including anthracyclines and taxanes, maximum concentration and the area under the curve were lower in pregnant women. 44 Although these alterations may theoretically influence maternal prognosis, we decided in an international consensus meeting focused on BCP that until more data are available, chemotherapy dosages for pregnant women should be calculated based on actual height and weight.
26 A previous analysis of our cohort showed that among the patients with BCP, survival rates did not differ between those who received chemotherapy during pregnancy and those who did so during the postpartum period. 24 The similar outcomes calculated in this series between pregnant (64% of patients received chemotherapy during pregnancy; n ϭ 200) and nonpregnant women is similarly reassuring. These observations suggest that chemotherapy during pregnancy can be administered as it is in nonpregnant women (with chemotherapy dosing based on body surface area), despite the altered pharmacokinetics during pregnancy.
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Apart from maternal safety, fetal safety is also considered when patients are counseled. Chemotherapy exposure during the second and third trimesters of pregnancy did not impair neonatal outcome. The rate of congenital malformations was not increased, although the neonates were more commonly born before the 37th week of gestation (49.6% compared with 10% to 15% in the general population).
24
Long-term cardiac and neurodevelopmental assessments of children exposed to chemotherapy in utero prospectively have been documented. A recent interim analysis did not show sequelae, although prematurity was associated with impaired cognitive development. 10 Taken together, the available data confirm maternal and fetal safety when breast cancer is treated during pregnancy. Standard treatment during pregnancy, including chemotherapy, adds to an optimal maternal outcome. This outcome now seems to be comparable to that of nonpregnant patients. In addition, the administration of chemotherapy during pregnancy contributes to fewer preterm deliveries and thus also to improved fetal outcome.
Our study design has some limitations. Data were retrospectively pooled from different hospitals from different countries. The control group came from one hospital only. However, it was chosen to create a more homogeneous control group, with few missing data. Histologic data were not centrally confirmed, and information on family history of breast cancer was sparse. However, our study design precludes the small-sample bias and heterogeneity of previous studies, which have been the major limitations to drawing firm conclusions.
In conclusion, in the largest cohort study to date, to our knowledge, we found similar survival for patients with primary breast cancer diagnosed during pregnancy, when compared with nonpregnant patients with breast cancer, after adjusting for known prognostic factors. The observation that patients with BCP experience survival rates comparable to those of nonpregnant patients is important when they are counseled. Breast cancer treatment during pregnancy does not jeopardize maternal prognosis. 
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